December 4th [Today's Investment Strategy]

[FISCO Selected Stocks] [Material Stocks] JCR Pharma <4552> 727 yen (12/3) Human growth hormone preparations are the main products. Regarding the blood-brain barrier crossing type α-N-acetylglucosaminidase preparation (JR-446) developed by the company, the first administration to the first subject targeted at mucopolysaccharidosis type 3B (MPS3B) in clinical phase 1/2 trials in Japan was announced. MPS3B is being jointly developed and commercialized with Medipal Holdings <7459>.

Fisco JapanDec 3 19:22 ET

Nikkei Edges Lower as Traders Brace for Nvidia Earnings

MT NewswiresNov 20 01:47 ET

MediPal Holdings Merges Subsidiaries to Streamline Sales Network, Medical Equipment Business

MT NewswiresNov 19 18:59 ET

Chordia Research Memo (1): Advancing the development of potential blockbuster anticancer drugs by a biotech venture that may become a block inc.

Chordia Therapeutics <190A> was founded by drug discovery researchers spun out from takeda pharmaceuticals sp adr <4502>, specializing in the development of small molecule anticancer drugs. The core business ranges from exploratory research to clinical research, with in-house manufacturing and sales through partnership strategies domestically, aiming for early profitability by licensing out overseas. Listed on the Tokyo Stock Exchange Growth Market in June 2024.

Fisco JapanNov 18 23:01 ET

Medipal Holdings: Confirmation letter

EDINETNov 12 19:56 ET · Announcements

Medipal Holdings: Semi-Annual Report - 116th Term (2024/04/01 - 2025/03/31)

EDINETNov 12 19:54 ET · Announcements